Patent Settlements May Break EU Law
UK’s Paroxetine Referral Raises Competition Issues
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.
You may also be interested in...
The UK’s Competition and Markets Authority has welcomed an EU Court of Justice ruling that settling patent disputes can break EU law by restricting competition. The case involved so-called "pay for delay" settlements regarding generic competitors to GlaxoSmithKline's antidepressant Seroxat (paroxetine).
The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.